New drug cocktail aims to fight incurable liver cancer

NCT ID NCT05320692

Ongoing Disease control Sponsor: Jiangsu HengRui Medicine Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 3 trial tests whether adding two drugs (camrelizumab and rivoceranib) to a standard liver cancer procedure (TACE) helps people with incurable liver cancer live longer without their disease getting worse. About 423 participants are randomly assigned to get either the combination or TACE alone. The study is active but no longer recruiting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: camrelizumab and rivoceranib (apatinib)
What this could lead to: If successful, this combination could offer a new treatment option to slow liver cancer progression and extend survival for people with incurable disease.
What could go wrong: This is an early-phase 3 trial, so results are not yet confirmed. The combination may cause more side effects than TACE alone, and it may not improve outcomes for all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for HEPATOCELLULAR CARCINOMA are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

hepatocellular carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

HEPATOCELLULAR CARCINOMA

Contacts and locations

Locations

Zhongshan Hospital, Fudan University

Shanghai, Shanghai Municipality, 200032, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.